Medipal Holdings Corporation · TSE:7459
Medipal — FY2024 Earnings Presentation
34 slides from Medipal's earnings presentation, May 13, 2025
Slide 1: Financial Results for the Fiscal Year Ended March 31, 2025
May. 13, 2025 Financial Results for the Fiscal Year Ended March 31, 2025 Expand, Support, and Connect “Pharmaceuticals, Health, and Beauty” an Orchestra in Support of People's Health The MEDIPAL Group aims to realize a society in which everyone can live with physical and mental well-being and to enh
Slide 2: Contents
Contents 1 Financial Results for the FY Ended March 31, 2025 2 Major Initiatives and Outlook for the FY Ending March 2026 3 Shareholder Returns The MEDIPAL Group has three business segments: Regarding the description of the business period ・ Prescription Pharmaceutical Wholesale Business (MEDICEO Bu
Slide 3: Management Philosophy and 2027 Medium-Term Vision
Management Philosophy: Contributing to people’s health and the advancement of society through creation of value in distribution Moving forward as one under the banner of "Change the Oroshi" 2027 MEDIPAL Medium-Term Vision MEDIPAL Group's Vision Oroshi Our mission is to deliver Hoping this precious d
Slide 4: Overview of Financial Results for FY2024
Overview of Financial Results for FY2024 The Core businesses performed steady Implementing strategic investments to achieve our vision and ensure sustainable growth Strengthening and Sales of prescription drugs are growing strongly, *Data from Encise Inc. （NHI Drug Price base） expanding core busin
Slide 5: FY2024 Consolidated Results [YoY Change]
FY2024 Consolidated Results [YoY Change] Net Sales growth in all business segments, with Net Sales and Operating Profit reached record levels Adjusted operating profit, excluding the impact of growth investment-related expenses, also increased Amount YoY Change Change factors from FY2023 Net Sales ¥
Slide 6: FY2024 Consolidated Results [Compared to forecast]
FY2024 Consolidated Results [Compared to forecast] Achieved consolidated sales forecast driven by MEDICEO business Operating Profit well above forecast as SG&A costs were lower than forecast due to delay in business investments Amount Difference from Forecast Reasons for the difference from forecast
Slide 7: FY2024 MEDICEO Business [YoY Change]
FY2024 MEDICEO Business [YoY Change] With “the two A's (ALC and AR*)” Exceeded market growth due to strengthening sales of vaccine-related and growth products Achieved increased operating profit through increased gross profit and reduced SG＆A expenses Amount YoY Change Change factors from FY2023 • P
Slide 8: FY2024 PALTAC Business [YoY Change]
FY2024 PALTAC Business [YoY Change] Sales and operating profit reached record levels • Sales increased due to activities that captured market changes such as increased opportunities to go out and inbound tourism • Profit increased due to increased sales and improved SG＆A expenses ratio due to produc
Slide 9: FY2024 AGRO&FOOD Business [YoY Change]
FY2024 AGRO＆FOOD Business [YoY Change] Gross profit increased due to solid sales and revised selling prices, offsetting higher costs due to the weak yen. Strengthening strategic investments in human resources, systems, and R&D for future growth Amount YoY Change Change factors from FY2023 • Animal H
Slide 10: Contents
Contents 1 Financial Results for the FY Ended March 31, 2025 2 Major Initiatives and Outlook for the FY Ending March 2026 3 Shareholder Returns Copyright © 2025 MEDIPAL HOLDINGS CORPORATION, All rights reserved. 10
Slide 11: Initiatives of MEDICEO Business
Initiatives of MEDICEO Business Contributing to stakeholders by increasing the value of “the two A’s (ALC and AR)” and improving productivity Strengthening ALC's safe, secure, convenient logistics with high functional network and AR’s information activities Patients・ Consumers Dispensing Medical pha
Slide 12: Initiatives of MEDICEO Business [ALC]
Initiatives of MEDICEO Business【ALC】 Optimizing the supply chain with customers to improve logistics efficiency and productivity Reducing total working hours amid increasing volume. Building productive logistics system through shared logistics Shortening shipping times and Introducing shared logisti
Slide 13: Initiatives of MEDICEO Business [AR]
Initiatives of MEDICEO Business 【AR】 Contributing to regional medical care by utilizing expertise and mobility As regional medical coordinators, we "connect" medical institutions, dispensing pharmacies, local governments, and patients Conducting surveys of local Employees who have passed AR the medi
Slide 14: New Business Initiatives [Global Development of Rare Disease Drugs]
New Business Initiatives [Global Development of Rare Disease Drugs] Development of JR-446 Progressing Well in Japan and the United States A drug developed by JCR Pharmaceuticals Co., Ltd. for mucopolysaccharidosis type IIIB*, a type of lysosomal storage disease. *Affects an estimated 500 to 1,000 in
Slide 15: Strategic Investments [PreMedica's Initiatives]
Strategic Investments [PreMedica's Initiatives] Promoting the synergies after PreMedica Inc. joined the group Analysis of intestinal flora contributes to early detection of disease and health risks specific to women MEDIPAL and PreMedica started joint May 2024 PreMedica joined MEDIPAL February ２025
Slide 16: Initiatives of PALTAC Business
Initiatives of PALTAC Business Steady implementation of key initiatives to achieve the mid-term management plan “Constructing the foundation for transformation through structural reform” Expansion of new products • Strengthening product procurement to meet market needs (strengthening connections w
Slide 17: Initiatives of AGRO&FOOD Business
Initiatives of AGRO＆FOOD Business MP AGRO Accelerating customer contributions and company growth through the widespread adoption of highly profitable in-house designed products MP Gokyo Food ＆ Chemical Integration of MEDIPAL FOODS* Accelerates growth by fully realizing synergies ＊The two compani
Slide 18: Sustainability Initiative (Reducing Environmental Impact)
Sustainability Initiative(Reducing Environmental Impact) Reducing greenhouse gas emissions by promoting a modal shift from trucks to rail transport Using 31-foot containers for the rail transport of pharmaceuticals between the Tokyo and Hokkaido from April 2025 Reduction of greenhouse gas emissions:
Slide 19: Forecast of Consolidated Results for the FY2025
Forecast of Consolidated Results for the FY2025 Forecasting Net Sales and Gross Profit growth in all business segments Included business investment costs for realizing the Medium-Term Vision in SG＆A expenses (¥ billion) Consolidated MEDICEO Business PALTAC Business AGRO＆FOOD Business % of Change % o
Slide 20: Contents
Contents 1 Financial Results for the FY Ended March 31, 2025 2 Major Initiatives and Outlook for the FY Ending March 2026 3 Shareholder Returns Copyright © 2025 MEDIPAL HOLDINGS CORPORATION, All rights reserved. 20
Slide 21: Cash Allocation
Cash Allocation Allocating cash in a balanced manner to growth investments needed to achieve the Medium- Term Vision, capital investments to build a robust logistics system, and shareholder returns Investment policy in the Medium-Term Vision and performance over the past 3 years Cumulative perform
Slide 22: Shareholder Returns
Shareholder Returns Considering the current financial situation, Resolved to increase the year-end dividend for FY2024 by ¥2 to ¥32 (annual dividend:¥62). Dividends Dividend amount and dividend payout ratio for the past 10 years The policy is to maintain or increase its dividend payout ratio Forec
Slide 23: 2027 MEDIPAL Medium-Term Vision
2027 MEDIPAL Medium-Term Vision Growing through business portfolio prioritizations and collaboration with partners Oroshi Change the 卸 Forever 〜Constant Innovation〜 FY2022 〜 FY2024 FY2025 FY2026 ～ Examined and implemented strategic Implemented a future-oriented Achieving sustainable growth investmen
Slide 24: Appendix
Appendix Copyright © 2025 MEDIPAL HOLDINGS CORPORATION, All rights reserved. 24
Slide 25: FY2024 Consolidated Statements
FY2024 Consolidated Statements (¥ billion) FY2023 FY2024 Results Forecast Results YoY Forecast Difference from （% of Net Sales） （% of Net Sales） （% of Net Sales） YoY Change % of Change % of Difference forecast Net Sales 3,558.7 3,660.0 3,671.3 +112.5 +3.2% +11.3 +0.3% Gross Profit 246.6 254.1 255.7
Slide 26: FY2024 MEDICEO Business
FY2024 MEDICEO Business (¥ billion) FY2023 FY2024 Results Results YoY （% of Net Sales) （% of Net Sales） YoY change % of Change Net Sales 2,295.7 2,370.2 +74.4 +3.2% Gross Profit 144.1 150.3 +6.2 +4.3% [6.28%] [6.34%] [＋0.07pts] SG&A Expenses 126.6 125.1 (1.4) (1.2%) [5.52%] [5.28%] [(0.24pts)] SG&A
Slide 27: FY2024 PALTAC Business
FY2024 PALTAC Business (¥ billion) FY2023 FY2024 Results Results YoY （% of Net Dales） （% of Net Dales） YoY Change % of Change Net Sales 1,151.9 1,188.0 +36.1 +3.1% Gross 86.3 88.9 +2.6 +3.0% Profit [7.50%] [7.49%] [(0.01pts)] SG&A 59.1 60.9 +1.7 +3.0% Expenses [5.14%] [5.13%] [(0.01pts)] Operating 2
Slide 28: FY2024 AGRO・FOOD Business
FY2024 AGRO・FOOD Business (¥ billion) FY2023 FY2024 Results Results YoY （% of Net Sales) （% of Net Sales) YoY change % of Change Net Sales 114.0 116.8 +2.8 +2.5％ Gross Profit 16.2 16.4 +0.1 +1.2% [14.26%] [14.07%] [(0.19pts)] SG&A Expenses 13.5 14.0 +0.4 +3.5% [11.87%] [11.98%] [＋0.11pts] SG&A Expen
Slide 29: FY2024 Results by Segment [Compared to forecast]
FY2024 Results by Segment [Compared to forecast] Achieved operating profits in the core businesses, MEDICEO and PALTAC Making strategic investments in the AGRO・FOOD Business for the future growth MEDICEO Business PALTAC Business AGRO・FOOD Business (¥ billion) Forecast Results Difference Forecast Res
Slide 30: Factors behind YoY changes in Gross Profit, Operating Profit and Ordinary Profit
Factors behind YoY changes in Gross Profit, Operating Profit and Ordinary Profit (¥ billion) +3.0 SG＆A expenses（Decrease） Non-Operating Income/Expenses Due to increased sales of MEDISKET (0.8) (7.5) +6.0 Due to increased sales (7.3) ＋4.6 (2.4) +0.1 Share of profit of entities +9.1 (3.0) Research acc
Slide 31: Factors behind YoY changes in Ordinary Profit to Profit attributable to Owners of Parent
Factors behind YoY changes in Ordinary Profit ,Profit before Income Taxes and Profit attributable to Owners of Parent (¥ billion) Extraordinary Income/Expenses +1.3 +3.2 rebound decreases (1.2) from last year Gain on sale Gain on of investment step securities acquisitions (1.9) Compensation income +
Slide 32: Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows (¥ billion) ＋60.5 (3.3) (25.9) 259.3 Cash Flows from 228.0 Investing Activities Cash Flows from Financing Activities Cash Flows from Operating Activities • Purchase of property, plant and • Purchase of treasury shares：(5.0) equipment：(8.8) • Acquisition of the c
Slide 33: Management Philosophy
Management Philosophy Contributing to people’s health and the advancement of society through creation of value in distribution Copyright © 2025 MEDIPAL HOLDINGS CORPORATION, All rights reserved. 33
Slide 34: Forward-Looking Statements
【Forward-Looking Statements】 These materials reflect analysis of available information and various trends as of the date on the cover. Risks and uncertainties affecting the Company’s business could cause actual results to differ materially from any projections presented in these materials. In the ev